<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833079</url>
  </required_header>
  <id_info>
    <org_study_id>TACR-0707</org_study_id>
    <nct_id>NCT00833079</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives are to establish the therapeutic equivalence of tacrolimus ointment&#xD;
      0.1%, manufactured by Taro Pharmaceuticals Inc. and ProtopicÂ® (tacrolimus), 0.1% topical&#xD;
      ointment (Astellas Pharma US, Inc.) and to show superiority over vehicle in the treatment of&#xD;
      moderate to severe atopic dermatitis.&#xD;
&#xD;
      The secondary objectives are to compare the adverse event (AE) profiles of the two ointments&#xD;
      and to investigate their systemic absorption at steady state.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ISGA score 0 or 1</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% change in BSA</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in EASI</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in ISGA</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and adverse event profile</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Tacrolimus 0.1% Taro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus 0.1% manufactured by Taro applied for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protopic - Tacrolimus 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protopic, Tacrolimus 0.1% applied for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tacrolimus vehicle applied for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus 0.1% manufactured by Taro</intervention_name>
    <description>Treatment applied as a thin layer to target area twice daily for 14 days</description>
    <arm_group_label>Tacrolimus 0.1% Taro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Protopic - Tacrolimus 0.1%</intervention_name>
    <description>Treatment applied as a thin layer to target area twice daily for 14 days</description>
    <arm_group_label>Protopic - Tacrolimus 0.1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Vehicle manufactured by Taro</intervention_name>
    <description>Treatment applied as a thin layer to target area twice daily for 14 days</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female, 18 years of age or older.&#xD;
&#xD;
          -  Patient has documented evidence that they have been unresponsive to alternative more&#xD;
             traditional therapies such as topical corticosteroids, or in the investigators&#xD;
             opinion, such first line therapy would be deemed inadvisable because of potential&#xD;
             risks to the patient.&#xD;
&#xD;
          -  If female and of child bearing potential, prepare to abstain from sexual intercourse&#xD;
             or use a reliable method of contraception during the study (e.g., condom, IUD, oral,&#xD;
             transdermal, injected or implanted hormonal contraceptives).&#xD;
&#xD;
          -  Have confirmed diagnosis of atopic dermatitis using the diagnostic features as&#xD;
             described by Hanifin and Rajka.&#xD;
&#xD;
          -  Have an IGSA score of 3 (moderate) or 4 (severe)&#xD;
&#xD;
          -  Have an affected Body Surface Area (BSA) of at least 20%&#xD;
&#xD;
          -  Have a minimum Eczema Area and Severity Index (EASI) score of at least 15&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mild atopic dermatitis as defined by IGSA score of 0 (clear), 1 (almost clear), or 2&#xD;
             (mild) OR %BSA affected less than 20% OR EASI Score of less than 15.&#xD;
&#xD;
          -  Clinically infected atopic dermatitis at the baseline visit. Tacrolimus is not&#xD;
             indicated for the treatment of clinically infected atopic dermatitis&#xD;
&#xD;
          -  Any dermatological condition other than atopic dermatitis that in the Investigator's&#xD;
             opinion may interfere with the evaluation of the patient's atopic dermatitis&#xD;
&#xD;
          -  Females who are pregnant, lactating or likely to become pregnant during the study.&#xD;
&#xD;
          -  History of allergy or sensitivity to tacrolimus, pimecrolimus, any macrolides such as&#xD;
             clindamycin erythromycin&#xD;
&#xD;
          -  Current diagnosis or history or any disease, which in the Investigators opinion would&#xD;
             contraindicate the use of immunosuppressants, including but not limited to human&#xD;
             immunodeficiency virus (HIV) and cancer.&#xD;
&#xD;
          -  Use of any nonsteroidal immunosuppressants&#xD;
&#xD;
          -  Regular use of intranasal or inhaled corticosteroids, greater than the equivalent of 2&#xD;
             mg of prednisone/day, within 14 days of the first dosing day.&#xD;
&#xD;
          -  Use of non-sedating histamines are not allowed for at least 7 days prior to the first&#xD;
             dosing day or throughout the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 28, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2009</study_first_posted>
  <last_update_submitted>January 19, 2014</last_update_submitted>
  <last_update_submitted_qc>January 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

